Search

Displaying results 7051 - 7060 of 7687 in total
  1. Drug

    D-Glutamine

    go.drugbank.com/drugs/DB02174
    Experimental

    It is the principal carrier of nitrogen in the body and is an important energy source for many cells.

    Synonyms: D-Glutamin, D-Glutamine
  2. Drug

    Oxalic Acid

    go.drugbank.com/drugs/DB03902
    Experimental

    It is used as an analytical reagent and general reducing agent. [PubChem]

  3. Drug

    Brasofensine

    go.drugbank.com/drugs/DB04857
    Experimental

    Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.

  4. Drug

    5-(5-(4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)pentyl)-3-methyl isoxazole

    go.drugbank.com/drugs/DB08724
    Experimental

    These are aromatic compounds containing an ether group substituted with a benzene ring. This medication is known to target genome polyprotein.

  5. Drug

    Fluciclatide

    go.drugbank.com/drugs/DB14842
    Investigational

    Fluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis.

  6. Drug

    Probiorinse

    go.drugbank.com/drugs/DB15870
    Experimental

    Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation solution that contains the probiotic bacteria Lactococcus lactis W136.

  7. Drug

    Saposin C

    go.drugbank.com/drugs/DB17380
    Investigational

    Recombinant, non-glycosylated Saposin C is an active ingredient of BXQ-350, which is a novel, investigational anti-neoplastic therapy.

  8. Drug

    SynOV1.1

    go.drugbank.com/drugs/DB17539
    Investigational

    SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech.

  9. Drug

    Pegsitacianine

    go.drugbank.com/drugs/DB19098
    Investigational

    Pegsitacianine is under investigation in clinical trial NCT05576974 (A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence

  10. Drug

    Arbaclofen

    go.drugbank.com/drugs/DB08891
    Investigational

    It has also been investigated as a treatment for spasticity due to multiple sclerosis and spinal cord injury.